Medtronic plc has announced FDA approval and US launch of the Intellis platform for the management of certain types of chronic intractable pain. The Intellis platform was designed to overcome limitations with current spinal cord stimulation (SCS) systems, such as battery performance, and can power the Evolve workflow which standardizes guidance and balances high-dose (HD) and low-dose (LD) therapy settings. It can also record and track patient activity 24/7 and is managed on the Samsung Galaxy Tab S2 tablet interface, enabling physicians to address the subjective and personal nature of chronic pain by monitoring progress and making modifications to better suit their patients' therapy needs.
Back problems are 1 of the top 10 most expensive medical conditions, with an estimated 30% of the 300,000 patients annually who undergo lumbosacral spine procedures developing chronic intractable pain. Chronic pain can negatively impact all aspects of a person's life, yet it remains under-recognized and undertreated. Neurostimulation has been proven to provide effective long-term pain relief and improve quality of life, in addition to being a treatment option for patients interested in trying a non-drug alternative.
Medtronic plc is headquartered in Dublin, Ireland.
Medtronic announces FDA approval and US launch of next generation spinal cord stimulator for chronic pain management. [news release]. Dublin, Ireland: Medtronic plc. September 18, 2017. http://newsroom.medtronic.com/phoenix.zhtml?c=251324&p=irol-newsArticle&ID=2301240. Accessed September 27, 2017.
This Week's Must Reads
Sex Differences Evident in Cognitive Decline in PD, Parkinsonism Relat Disord; ePub 2018 Feb 9; Cholerton, et al
IBD Associated with Lower Risk of Developing PD, Parkinsonism Relat Disord; ePub 2018 Feb 9; Camacho-Soto, et al
Dysgeusia, Side Effect of DBS, Can Be Reduced, J Clin Neurosci; ePub 2018 Feb 2; Carlson, et al
Leg Stereotypy Syndrome Common in Healthy Adults, J Neuro Neurosurg Psychiatry; ePub 2018 Jan 13; Lotia, et al
Adductor Focal Laryngeal Dystonia Impacts QOL, J Clin Mov Disord; ePub 2017 Dec 13; Stewart, et al
Must Reads in FDA Actions
Riptide Aspiration System Receives FDA Clearance, Medtronic news release; 2018 Jan 16
FDA Approves Vercise Deep Brain Stimulation System, Boston Scientific news release; 2017 Dec 11
FDA Approves Repatha to Prevent Stroke, Heart Attack, Amgen news release; 2017 Dec 1
FDA Clears Apple Watch Heart Rate Accessory, PharmaLive news release; 2017 Nov 30
FDA Approves Oral Option for Pediatric Epilepsy, UCB news release; 2017 Nov 6